Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

Vaccines are the key technology to combat existing and emerging infectious diseases.
However, increasing the potency, quality and durability of the vaccine response remains a …

A major challenge in cancer vaccine therapy is the efficient delivery of antigens and
adjuvants to stimulate a controlled yet robust tumour-specific T-cell response. Here, we …

Multiple nanotherapeutics have been approved for patients with cancer, but their effects on
survival have been modest and, in some examples, less than those of other approved …

Recent advances in several areas are rekindling interest and enabling progress in the
development of therapeutic cancer vaccines. These advances have been made in target …

Cancer immunotherapy can effectively inhibit cancer progression by activating the
autoimmune system, with low toxicity and high effectiveness. Some of cancer …

T cell dysfunction contributes to tumor immune escape in patients with cancer and is
particularly severe amidst glioblastoma (GBM). Among other defects, T cell lymphopenia is …

Research on tumor immunotherapy has made tremendous progress in the past decades,
with numerous studies entering the clinical evaluation. The cancer vaccine is considered a …

Advances in nanoparticle synthesis and engineering have produced nanoscale agents
affording both therapeutic and diagnostic functions that are often referred to by the …

Despite the tremendous potential of peptide-based cancer vaccines, their efficacy has been
limited in humans. Recent innovations in tumour exome sequencing have signalled the new …